Mumbai headquartered Sun Pharmaceutical Industries Limited, India’s largest drugmaker, acquired Lexington, MA-based Concert Pharmaceuticals Inc., for $576 million in cash. Sun Pharma offered Concert $8 per share, representing a premium of 16% to the stock’s last close.
Concert’s lead candidate, deuruxolitinib, is currently being evaluated in a late-stage study as a treatment for autoimmune condition alopecia areata.
Alopecia areata is an autoimmune disease in which the body’s immune system mistakenly attacks a person’s hair follicles, causing patchy or complete loss of hair on the scalp and body This condition affects up to approximately 1.5 million Americans at any given time and can be debilitating to their physical and psychological health.
Sun Pharma said its immediate focus would be to follow Concert’s plan to submit a marketing application for its lead candidate to the U.S. Food and Drug Administration (FDA) in the first half of this year.
“We are pleased to enter into this exciting transaction with Sun Pharma, which delivers substantial value to our shareholders and is the outcome of a thorough review process overseen by the Concert Board,” stated Roger Tung, Ph.D., president and CEO of Concert.
Last updated: December 26th, 2025
